Isabel Gonzalez-Alvarez
Overview
Explore the profile of Isabel Gonzalez-Alvarez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsume Y, Ashworth L, Bermejo Sanz M, Cicale V, Dressman J, Fushimi M, et al.
Mol Pharm
. 2024 Sep;
21(10):5315-5325.
PMID: 39311714
Biorelevant dissolution and its concept have been widely accepted and further developed to meaningfully predict the bioperformance of oral drug products. Biorelevant methodologies have been applied to design and optimize...
2.
Cabanero-Resta G, Sanchez-Dengra B, Ruiz-Picazo A, Bermejo M, Merino V, Gonzalez-Alvarez I, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794238
Itraconazole is a drug used in veterinary medicine for the treatment of different varieties of dermatophytosis at doses between 3-5 mg/kg/day in cats. Nevertheless, in Spain, it is only available...
3.
Gonzalez-Alvarez I, Ruiz-Picazo A, Selles-Talavera R, Figueroa-Campos A, Merino V, Bermejo M, et al.
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543284
The purpose of this study was to predict the in vivo bioequivalence (BE) outcome of valsartan (VALS, BCS class IV) from three oral-fixed combination products with hydrochlorothiazide (HCTZ, BCS class...
4.
Sanchez-Dengra B, Alfonso M, Gonzalez-Alvarez I, Bermejo M, Gonzalez-Alvarez M, Martinez-Manez R
Nanomedicine (Lond)
. 2023 Nov;
18(25):1799-1813.
PMID: 37990994
Glioblastoma is the most common and lethal brain cancer. New treatments are needed. However, the presence of the blood-brain barrier is limiting the development of new treatments directed toward the...
5.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, et al.
AAPS J
. 2023 Jun;
25(4):58.
PMID: 37291273
No abstract available.
6.
Sanchez-Dengra B, Garcia-Montoya E, Gonzalez-Alvarez I, Bermejo M, Gonzalez-Alvarez M
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242673
Currently, the mechanisms involved in drug access to the central nervous system (CNS) are not completely elucidated, and research efforts to understand the behaviour of the therapeutic agents to access...
7.
Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, et al.
AAPS J
. 2023 Apr;
25(3):45.
PMID: 37085637
Assessing in vivo performance to inform formulation selection and development decisions is an important aspect of drug development. Biopredictive dissolution methodologies for oral dosage forms have been developed to understand...
8.
Sanchez-Dengra B, Gonzalez-Alvarez I, Bermejo M, Gonzalez-Alvarez M
Int J Pharm
. 2023 Feb;
636:122759.
PMID: 36801479
The blood-brain barrier (BBB) limits the access of substances to the central nervous system (CNS) which hinders the treatment of pathologies affecting the brain and the spinal cord. Nowadays, research...
9.
Gonzalez-Alvarez I, Sanchez-Dengra B, Rodriguez-Galvez R, Ruiz-Picazo A, Gonzalez-Alvarez M, Garcia-Arieta A, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559059
Some years ago, excipients were considered inert substances irrelevant in the absorption process. However, years of study have demonstrated that this belief is not always true. In this study, the...
10.
Siafaka P, Gundogdu E, Caglar E, Ozgenc E, Gonzalez-Alvarez M, Gonzalez-Alvarez I, et al.
Curr Drug Deliv
. 2022 Sep;
20(9):1288-1313.
PMID: 36082850
Background: Currently, there is ongoing research in the pharmaceutical technology field to develop innovative drug delivery systems with improved therapeutic efficacy. Objectives: Although there is a high need for new...